aMoon Fund

Ultima Genomics is unleashing the power of genomics at scale. Ultima Genomics drives the scale of genomic information to enable unprecedented advances in biology and improvements in human health. The company was founded in 2016 and is based in Newark, California.

Eleos Health is a developer of a SaaS based tool that track mental health.

Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It focuses on the development and implementation of proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases.

MDClone Ltd. is a company that specializes in software designed to analyze medical records while ensuring patient privacy. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients. This innovative approach allows researchers to study disease behavior, medical practices, and various healthcare dynamics without exposing actual patient data. The platform creates fictitious individuals with unique characteristics, preserving essential relationships between them, thus maintaining the integrity of medical information while safeguarding privacy. By enabling health organizations to harness the value of their data assets, MDClone significantly enhances the ways medical information is gathered, analyzed, and utilized in research and service delivery.

Scipher Medicine is a biotechnology company based in Waltham, Massachusetts, that focuses on developing a molecular technology platform to predict patient responses to drug therapies, particularly in cardiovascular and autoimmune diseases. The company offers several diagnostic tests, including PrismDx, which identifies patients who may not respond to specific medications, PrismRA for patients with rheumatoid arthritis, and PrismUC for those with ulcerative colitis. These tests enable healthcare providers to prescribe more suitable alternative therapies for patients who are unlikely to benefit from traditional treatments. Scipher Medicine emphasizes the importance of providing scientifically backed data to improve patient outcomes and enhance treatment decisions. The company has also established a strategic partnership with Ambry Genetics Corporation to further advance its capabilities. Founded in 2014, Scipher Medicine was previously known as DZZOM Delaware Corporation before changing its name in 2015.

Omada Health, Inc. is a digital healthcare company that develops online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, with an additional office in Atlanta, the company collaborates with employers and health plans to identify individuals at risk for preventable chronic conditions such as prediabetes, diabetes, hypertension, and heart disease. Omada's programs are personalized to address the evolving needs of participants, offering support in areas like diabetes prevention, type 2 diabetes management, and behavioral health. The company integrates professional health coaching, connected health devices, real-time data, and personalized feedback to achieve clinically significant outcomes. Omada Health is recognized as the largest provider of the National Diabetes Prevention Program by the Centers for Disease Control and Prevention (CDC).

Eleos Health is a developer of a SaaS based tool that track mental health.

Eleos Health is a developer of a SaaS based tool that track mental health.

Mobilion Systems, Inc. is a biotechnology company based in Chadds Ford, Pennsylvania, that specializes in advanced ion mobility separation technology known as structures for lossless ion manipulation (SLIM). Founded in 2015, the company focuses on identifying and analyzing difficult-to-detect molecules, particularly those relevant to biologic therapeutics and disease diagnostics. Mobilion's innovative SLIM technology allows for the separation and detection of clinically significant biomolecules that conventional instruments struggle to identify. By providing enhanced sensitivity, resolution, and throughput, Mobilion's analytical instruments support the development of improved therapeutics and enable earlier disease detection, ultimately aiming to address diseases at their core rather than merely treating symptoms.

We're a digital healthcare company on a mission to enhance patients outcome by helping doctors and companies make better decisions through the generation of reliable synthetic data and by developing decision support systems

DayTwo Ltd. is a precision medicine company based in Tel Aviv-Yafo, Israel, founded in 2015. The company operates a web-based platform that leverages gut microbiome analysis to provide personalized health solutions, particularly for metabolic diseases such as diabetes, prediabetes, clinical obesity, and non-alcoholic fatty liver disease. DayTwo's innovative approach, grounded in research published in reputable scientific journals, recognizes that individuals react differently to foods, making tailored dietary recommendations essential for effective treatment. By analyzing stool samples, DayTwo creates individualized Food Prescriptions™ designed to optimize blood sugar levels, enhance energy, manage appetite, and support weight loss. Its services are delivered through a digital app, facilitated by Certified Diabetes Care and Education Specialists and Registered Dietitians, enabling users to monitor their progress and communicate with care providers. DayTwo tracks clinical outcomes such as A1C and Time In Range, offering a performance-based fee structure for users who adhere to its program.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, founded in 2008. The company specializes in developing diagnostic tests aimed at predicting a woman's individualized risk of premature birth, preeclampsia, and other pregnancy-related complications. By utilizing proprietary biomarkers, Sera Prognostics seeks to address the significant economic and healthcare challenges associated with premature births, impacting infants, families, and society at large. The company has licensed advanced serum proteomics technology and innovative peptides from Brigham Young University and the University of Utah to support its research and development efforts.

AltruBio is a biopharmaceutical company that specializes in developing targeted antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases. Founded in 2000, the company has its research and development base in Taipei, Taiwan, and operates globally with its principal office in the San Francisco Bay Area. AltruBio focuses on addressing unmet medical needs by discovering and developing innovative therapeutics. Its research scientists utilize a robust discovery platform to identify and validate new antibody treatments. The company has a promising pipeline of therapeutic antibodies aimed at various conditions, including autoimmune diseases and multiple types of cancer, such as pancreatic, stomach, colorectal, ovarian, and lung cancer, which are in various stages of development.

Samumed, LLC is a biopharmaceutical company focused on small molecule drug development aimed at oncology and degenerative diseases. Founded in 2007 and based in San Diego, California, the company utilizes its expertise in Wnt pathway modulation to create therapeutics for tissue-level regeneration. Among its key products are SM04690, an intra-articular injection for treating knee osteoarthritis, and SM07883, which is designed to mitigate disease pathology. Samumed is committed to advancing regenerative medicine through its innovative platform, which seeks to improve patient health by addressing a variety of degenerative conditions.

Scipher Medicine is a biotechnology company based in Waltham, Massachusetts, that focuses on developing a molecular technology platform to predict patient responses to drug therapies, particularly in cardiovascular and autoimmune diseases. The company offers several diagnostic tests, including PrismDx, which identifies patients who may not respond to specific medications, PrismRA for patients with rheumatoid arthritis, and PrismUC for those with ulcerative colitis. These tests enable healthcare providers to prescribe more suitable alternative therapies for patients who are unlikely to benefit from traditional treatments. Scipher Medicine emphasizes the importance of providing scientifically backed data to improve patient outcomes and enhance treatment decisions. The company has also established a strategic partnership with Ambry Genetics Corporation to further advance its capabilities. Founded in 2014, Scipher Medicine was previously known as DZZOM Delaware Corporation before changing its name in 2015.

AbSci, LLC is a biotechnology company based in Portland, Oregon, specializing in protein production technologies for the biopharmaceutical industry. Founded in 2011, AbSci has developed SoluPro, an innovative expression system utilizing genetically engineered E. coli to facilitate the scalable and cost-effective production of antibodies, antibody fragments, and other soluble recombinant proteins. This technology significantly lowers production costs for both novel and existing biologics, enhancing the efficiency of drug discovery and manufacturing processes. AbSci's therapeutic proteins and antibodies play vital roles in treatments for cancer, hormone-related conditions, autoimmune diseases, and blood disorders. The company's approach integrates biologic drug discovery with cell line development, positioning it as a leader in the advancement of next-generation therapeutics.

Ibex Medical Analytics Ltd is a company based in Tel Aviv, Israel, that specializes in developing AI-based systems for cancer diagnosis in pathology. Its flagship product, the Ibex Second Read system, operates by analyzing pathology cases concurrently with human pathologist reviews, identifying discrepancies between the pathologist's diagnoses and its own analytical results. The founders of Ibex were motivated by the potential of artificial intelligence to enhance cancer care and improve patient outcomes. The company brings together a multidisciplinary team of entrepreneurs, data scientists, software engineers, and medical experts, all focused on advancing cancer diagnostics through the application of AI, data science, and image analysis.

Viracta Therapeutics specializes in developing innovative treatments for cancers linked to the Epstein-Barr Virus. The company is advancing its proprietary viral gene activation therapy, which aims to effectively target and address these virus-associated malignancies. In addition to its primary focus on Epstein-Barr Virus-related cancers, Viracta is also exploring opportunities to tackle other serious diseases associated with viral infections. Through its research and therapeutic advancements, the company seeks to improve outcomes for patients suffering from these challenging health conditions.

Viracta Therapeutics specializes in developing innovative treatments for cancers linked to the Epstein-Barr Virus. The company is advancing its proprietary viral gene activation therapy, which aims to effectively target and address these virus-associated malignancies. In addition to its primary focus on Epstein-Barr Virus-related cancers, Viracta is also exploring opportunities to tackle other serious diseases associated with viral infections. Through its research and therapeutic advancements, the company seeks to improve outcomes for patients suffering from these challenging health conditions.

SOPHiA GENETICS combines deep expertise in life sciences and medical disciplines with mathematical capabilities in data computing. The company aims to bring data analytics solutions to the market, to support healthcare professionals by maximizing the power of data-driven medicine. It achieves this mission through the adoption of SOPHiA AI, which is built using techniques such as statistical inference, pattern recognition, and machine learning. This enables SOPHiA to provide equal benefits to all users, unite experts in a gold standard health-tech platform, and motivate expert knowledge sharing for a sustainable impact on future patients. It contributes to making the global healthcare system more sustainable. By helping healthcare professionals leverage their expertise and work together as a community, patients can receive equal access to better diagnoses and treatments. It combines the first two pillars of data-driven medicine, genomics, and radionics, the company ensures that the data used to help patients. Founded by Jurgi Camblong, Lars Steinmetz, and Pierre Hutter, SOPHiA GENETICS was incorporated in 2011. It has offices in Boston, Massachusetts, Switzerland, and France.

Harnessing the innate mechanism of gene activation, MiNA Therapeutics’ platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape in cancer and other diseases.

Mobilion Systems, Inc. is a biotechnology company based in Chadds Ford, Pennsylvania, that specializes in advanced ion mobility separation technology known as structures for lossless ion manipulation (SLIM). Founded in 2015, the company focuses on identifying and analyzing difficult-to-detect molecules, particularly those relevant to biologic therapeutics and disease diagnostics. Mobilion's innovative SLIM technology allows for the separation and detection of clinically significant biomolecules that conventional instruments struggle to identify. By providing enhanced sensitivity, resolution, and throughput, Mobilion's analytical instruments support the development of improved therapeutics and enable earlier disease detection, ultimately aiming to address diseases at their core rather than merely treating symptoms.

Seer is a developer of a life sciences and health data platform intended to facilitate early, pre-symptomatic detection of chronic life-threatening diseases. The company's platform captures and translates molecular insights from the proteome with improved accuracy and speed, enabling healthcare professionals to detect cancer and neurological diseases, drive earlier treatment and improve patient outcomes.

Nectin Therapeutics is developing novel monoclonal antibodies directed towards members of the Nectin family of receptors and ligands that have major roles in the immune checkpoint mechanisms relevant for cancer immune therapy. These novel antibodies are developed for the treatment of solid and hematological malignancies.

Curesponse, a diagnostics company, develops a tissue culture system for modelling cancer growth and drug response. The company develops an online platform for patients and clinicians to send samples of their tumor to be tested. Curesponse was founded in 2017 and is based in Tel Aviv-Yafo, Israel.

AtaCor Medical, Inc. develops pacemaker system that keeps the heart and veins free from pacing leads and hardware. It offers AtaCor EV Temporary Pacing System, an implantable temporary pacing system that uses a parasternal approach for implantable, extravascular temporary pacing. The company’s AtaCor EV Temporary Pacing System advances a custom pacing lead into the extracardiac tissue between the ribs and pericardium to restore cardiac rhythm for patients. AtaCor Medical, Inc. was incorporated in 2014 and is based in San Clemente, California.

Apos Medical Assets Ltd. specializes in non-surgical orthopedic services, primarily through its innovative AposTherapy program. Founded in 2004 and based in New York, the company has expanded its operations to Israel, Singapore, and the United Kingdom. AposTherapy was developed by orthopedic and sports medicine experts in response to advancements in biomechanics and the neuromuscular system's role in orthopedic rehabilitation. The treatment involves a personalized program that uses a patented foot-worn biomechanical device, delivered by specially-trained physical therapists. Patients engage in the therapy during their daily activities for about an hour each day, addressing biomechanical abnormalities associated with various orthopedic conditions. AposTherapy aims to restore proper motor patterns and empower patients by enhancing their understanding of their conditions. The company monitors patient progress closely and shares clinical outcomes to provide objective measures of improvement. With over 50,000 patients treated worldwide and multiple research publications, AposHealth is committed to advancing knowledge and improving the quality of life for individuals with musculoskeletal disorders.

Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, founded in 2017. It specializes in developing advanced CRISPR solutions, including its proprietary DETECTR technology, which allows for the detection of specific nucleic acids in samples, aiding in diagnostics for various conditions such as bacterial infections, cancer, and viral infections. The company focuses on democratizing disease detection through accessible point-of-care tests that can simultaneously identify multiple health issues. Additionally, Mammoth offers CRISPR-Cas systems for genome editing, targeting therapeutic applications in immuno-oncology, autoimmune diseases, and liver diseases. Its innovative solutions are utilized across diverse sectors, including healthcare, agriculture, environmental monitoring, and biodefense. Co-founded by CRISPR pioneer Jennifer Doudna, Mammoth Biosciences is supported by notable institutional and individual investors, reflecting its commitment to harnessing CRISPR technology for significant advancements in life sciences.

NanoGhosts’ technology is based on its founder’s research, that the Technion's commercial unit has patented in the U.S. and Europe.

Seer is a developer of a life sciences and health data platform intended to facilitate early, pre-symptomatic detection of chronic life-threatening diseases. The company's platform captures and translates molecular insights from the proteome with improved accuracy and speed, enabling healthcare professionals to detect cancer and neurological diseases, drive earlier treatment and improve patient outcomes.

Vocalis Health is a health technology company based in Tel Aviv, Israel, with an additional office in the United States. Founded in 2019, the company specializes in developing an artificial intelligence-based platform that utilizes vocal biomarkers to monitor and diagnose health conditions through voice analysis. The technology enables healthcare providers to remotely interact with patients, facilitating screening and monitoring for various voice-affecting diseases, including chronic respiratory and cardiac conditions, as well as mental health issues such as depression. By leveraging machine learning and deep learning techniques, Vocalis Health's platform allows for the assessment of a patient's health status via voice recordings, providing insights that can help evaluate the severity or presence of specific health conditions.

Igentify Ltd is a company focused on preventive healthcare through genomic products and services, established in 2016 and headquartered in Haifa, Israel. The company offers FamilyFirst, an expanded carrier screening specifically designed for the Jewish and Israeli populations. Igentify operates a digital genetic platform that enhances accessibility and usability of genomic information for clinicians, laboratories, and patients. This platform addresses the increasing demand for genomic medicine by streamlining the process of genetic testing. It includes features such as digitizing genetic assistants, customizing educational resources, collecting consent, analyzing data, and providing tailored results through video. By simplifying these steps, Igentify enables test providers to efficiently gather necessary information from patients across various devices.

MDClone Ltd. is a company that specializes in software designed to analyze medical records while ensuring patient privacy. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients. This innovative approach allows researchers to study disease behavior, medical practices, and various healthcare dynamics without exposing actual patient data. The platform creates fictitious individuals with unique characteristics, preserving essential relationships between them, thus maintaining the integrity of medical information while safeguarding privacy. By enabling health organizations to harness the value of their data assets, MDClone significantly enhances the ways medical information is gathered, analyzed, and utilized in research and service delivery.

DayTwo Ltd. is a precision medicine company based in Tel Aviv-Yafo, Israel, founded in 2015. The company operates a web-based platform that leverages gut microbiome analysis to provide personalized health solutions, particularly for metabolic diseases such as diabetes, prediabetes, clinical obesity, and non-alcoholic fatty liver disease. DayTwo's innovative approach, grounded in research published in reputable scientific journals, recognizes that individuals react differently to foods, making tailored dietary recommendations essential for effective treatment. By analyzing stool samples, DayTwo creates individualized Food Prescriptions™ designed to optimize blood sugar levels, enhance energy, manage appetite, and support weight loss. Its services are delivered through a digital app, facilitated by Certified Diabetes Care and Education Specialists and Registered Dietitians, enabling users to monitor their progress and communicate with care providers. DayTwo tracks clinical outcomes such as A1C and Time In Range, offering a performance-based fee structure for users who adhere to its program.

Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL02, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer, T-cell Acute Lymphoblastic Leukemia, Desmoid Tumors and Multiple Myeloma (in collaboration with Novartis).

Ibex Medical Analytics Ltd is a company based in Tel Aviv, Israel, that specializes in developing AI-based systems for cancer diagnosis in pathology. Its flagship product, the Ibex Second Read system, operates by analyzing pathology cases concurrently with human pathologist reviews, identifying discrepancies between the pathologist's diagnoses and its own analytical results. The founders of Ibex were motivated by the potential of artificial intelligence to enhance cancer care and improve patient outcomes. The company brings together a multidisciplinary team of entrepreneurs, data scientists, software engineers, and medical experts, all focused on advancing cancer diagnostics through the application of AI, data science, and image analysis.

Theranica is a medical device company that has combined neuromodulation therapy with modern wireless technology to develop proprietary wearable solutions that address various medical conditions and disease states. The noninvasive and therapeutic 'smart' patches are controlled by a smartphone app to allow for personalized, portable, and affordable care. The patch consists of a proprietary 'smart' chip that delivers electrical pulses to neuro-modulate the sensory nerves under the skin. The first application of the technology is for treatment of migraine headaches.

AtaCor Medical, Inc. develops pacemaker system that keeps the heart and veins free from pacing leads and hardware. It offers AtaCor EV Temporary Pacing System, an implantable temporary pacing system that uses a parasternal approach for implantable, extravascular temporary pacing. The company’s AtaCor EV Temporary Pacing System advances a custom pacing lead into the extracardiac tissue between the ribs and pericardium to restore cardiac rhythm for patients. AtaCor Medical, Inc. was incorporated in 2014 and is based in San Clemente, California.

NobioTM developed game-changing technology with the goal to prevent medical device contamination indefinitely, as the first and only fully-integrated anti-biofilm solution. The technology core consists of extremely potent particles which are covered with a high concentration of highly-active anti-microbial structures that kill bacteria upon contact. The NobioTM particles can be permanently embedded in many products and materials to inhibit formation of biofilm, indefinitely.

Medial EarlySign Ltd develops a healthcare technology for healthcare providers to identify risks for critical threats. It offers AlgoMarkers and AlgoAnalyzer, predictive engines that allow healthcare organizations to diagnose large number of patients and deliver clinical rigor and algorithmic insights. The company was founded in 2009 and is based in Kfar Malal, Israel.

Karius, Inc. is a life sciences company dedicated to generating genomic insights for infectious diseases. It offers the Karius Test, a non-invasive blood test that utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. Karius also provides laboratory services for pathogen biomarker detection tailored for biopharmaceutical companies. Founded in 2014, the company is based in Redwood City, California, with an additional office in Menlo Park. Its laboratory holds CLIA certification and CAP accreditation, allowing it to conduct high-complexity clinical laboratory testing to support rapid clinical decision-making.

Cartiheal Ltd., a medical device company, develops implants for the regeneration of cartilage and bone disorders. The company offers Agili-C, an off the shelf and cell-free implant that regenerates hyaline cartilage and its underlying subchondral bone. Its implant is used for the treatment of focal articular cartilage and osteochondral defects. The company was founded in 2009 and is based in Kfar Sava, Israel.